Geron Corporation (GERN)

Market Cap	2.41B
Revenue (ttm)	29.48M
Net Income (ttm)	-201.19M
Shares Out	604.50M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,403,202
Open	3.760
Previous Close	3.790
Day's Range	3.725 - 4.000
52-Week Range	1.640 - 5.340
Beta	0.51
Analysts	Strong Buy
Price Target	6.95 (+74.19%)
Earnings Date	Nov 7, 2024

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquarte...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 1996
• Employees: 141
• Stock Exchange: NASDAQ
• Ticker Symbol: GERN
• Website: https://www.geron.com

Financial Performance

In 2023, Geron's revenue was $237,000, a decrease of -60.23% compared to the previous year's $596,000. Losses were -$184.13 million, 29.8% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for GERN stock is "Strong Buy." The 12-month stock price forecast is $6.95, which is an increase of 74.19% from the latest price.

Price Target

$6.95

(74.19% upside)

Analyst Consensus: Strong Buy